Company news
Tango Therapeutics, Inc. news in 2024
Tango Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 2, 2024
Tango Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
November 26, 2024
Tango Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights
November 5, 2024
Tango Therapeutics Reports Positive TNG462 Clinical Data and Provides Update on PRMT5 Development Program
November 5, 2024
Tango Therapeutics to Participate in Upcoming Investor Conferences
August 27, 2024
Tango Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Highlights
August 6, 2024
Tango Therapeutics to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 4, 2024
Tango Therapeutics Announces Discontinuation of TNG348 Program
May 22, 2024
Tango Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Highlights
May 7, 2024
Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights
March 17, 2024
Tango Therapeutics to Highlight Preclinical Data on Precision Oncology Pipeline at the American Association for Cancer Research (AACR) Annual Meeting 2024
March 4, 2024
Tango Therapeutics to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
January 30, 2024
Tango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG348 in Patients with BRCA1/2-Mutant and Other HRD+ Cancers
January 2, 2024